A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
Clinical trial NCT03762850 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03762850
- Sponsor
- Travere Therapeutics, Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-12-11
- Primary completion
- 2023-08-07
- Enrollment
- 406
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.